AbbVie gets rights to Lupin's MALT1 program

Lupin Ltd. (NSE:LUPIN; BSE:500257) granted AbbVie Inc. (NYSE:ABBV) exclusive, worldwide rights to a portfolio of mucosa-associated lymphoid tissue lymphoma translocation gene 1 (MALT1) inhibitors, which the U.S. pharma intends to develop for hematological cancers.

AbbVie will pay Lupin $30 million up front. The Indian company is eligible for $947 million in milestones, plus double-digit royalties, and will retain the program’s commercial rights in India...